GENFIT Share Price Euronext Paris
Stocks
FR0004163111
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Other stock markets
|
||
| 13.93 EUR | 0.00% |
|
| 03/07 | Genfit soars on news of U.S. reimbursement for a product |  |
| 03/07 | Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement | MT |
| Market Cap | 69Cr 79Cr 64Cr 59Cr 111.43Cr 7.52TCr 113.3Cr 759.7Cr 298.34Cr 3.7TCr 295.9Cr 289.46Cr 13TCr | P/E 2026 * |
72.5x | P/E 2027 * | 91.5x |
|---|---|---|---|---|---|
| Enterprise Value | 64Cr 73Cr 59Cr 55Cr 103.85Cr 7.01TCr 105.6Cr 708.05Cr 278.05Cr 3.45TCr 275.78Cr 269.78Cr 12TCr | EV / Sales 2026 * |
6.75x | EV / Sales 2027 * | 5.3x |
| Free-Float |
86.88% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 58 | 16/09/2019 |
Thomas Baetz
DFI | Director of Finance/CFO | 52 | 22/04/2021 |
Pejvack Motlagh
CTO | Chief Tech/Sci/R&D Officer | - | 27/11/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 16/06/2017 | |
| Director/Board Member | 54 | 15/09/1999 | |
| Director/Board Member | 58 | 16/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.58% | +2.06% | +2.92% | +10.86% | 5.04TCr | |
| -1.30% | -0.65% | +390.29% | +593.72% | 4.06TCr | |
| -0.73% | +0.81% | +25.44% | -5.37% | 3.49TCr | |
| -1.10% | -3.30% | +18.09% | +55.43% | 3.37TCr | |
| +1.21% | -0.79% | +4.46% | +35.18% | 2.63TCr | |
| -1.94% | +0.87% | - | - | 1.71TCr | |
| -0.19% | -5.47% | +62.74% | +120.93% | 1.53TCr | |
| -8.40% | -28.96% | +39.43% | +41.43% | 1.06TCr | |
| +0.23% | -0.58% | +13.76% | +21.11% | 1.37TCr | |
| Average | -1.27% | -2.12% | +69.64% | +109.16% | 2.7TCr | |
| Weighted average by Cap. | -0.69% | -0.03% | +85.06% | +132.36% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 9.52Cr 11Cr 8.78Cr 8.11Cr 15Cr 1.04TCr 16Cr 104.91Cr 41Cr 511.35Cr 41Cr 40Cr 1.76TCr | 12Cr 14Cr 11Cr 10Cr 19Cr 1.3TCr 20Cr 131.44Cr 52Cr 640.64Cr 51Cr 50Cr 2.2TCr |
| Net income | 1.86Cr 2.13Cr 1.72Cr 1.59Cr 3.01Cr 203.11Cr 3.06Cr 21Cr 8.06Cr 100.06Cr 8Cr 7.82Cr 343.98Cr | 33.33T 38.1T 30.74T 28.39T 53.88T 36.34L 54.78T 4L 1L 17.9L 1L 1L 61.55L |
| Net Debt | -4.69Cr -5.36Cr -4.32Cr -3.99Cr -7.58Cr -511.02Cr -7.7Cr -52Cr -20Cr -251.75Cr -20Cr -20Cr -865.45Cr | -5.69Cr -6.5Cr -5.25Cr -4.85Cr -9.19Cr -620.12Cr -9.35Cr -63Cr -25Cr -305.49Cr -24Cr -24Cr -1.05TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
